Cambridge, UK-based Inivata has announced a collaboration with Princess Margaret Cancer Center to run two trials of its its InVisionFirst – Lung and RaDaR liquid biopsy tests.
The Accelerating Lung Cancer Diagnosis through Liquid Biopsy (ACCELERATE) trial is comparing liquid biopsy-guided treatment of advanced non-small cell lung cancer (NSCLC) to treatment guided by tissue profiling.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?